Nluc Reporter Cell Line - SIHA

SiHa is a highly characterized human cervical squamous cell carcinoma cell line, originally isolated from primary tumor tissue of a 55-year-old female patient. Growing as adherent, epithelial-like monolayers, SiHa is a cornerstone model in gynecological oncology, distinctively known for harboring integrated copies of the human papillomavirus type 16 (HPV-16) genome, which drives its malignant phenotype through the expression of E6 and E7 oncoproteins. The Nluc Reporter Cell Line - SiHa elevates this foundational model through the stable genetic integration of the NanoLuc (Nluc) reporter gene. NanoLuc is a highly engineered, exceptionally compact (19.1 kDa) luciferase enzyme derived from the deep-sea shrimp Oplophorus gracilirostris. When catalyzed by its specific substrate, furimazine, it produces a sustained, high-intensity luminescent signal that is frequently up to 100 times brighter than conventional firefly luciferase. Most importantly, the engineered Nluc-SiHa cells strictly retain the biological identity, morphology, and critical HPV-driven molecular mechanisms of the parental line, providing a biologically authentic and highly sensitive platform for advanced cervical cancer research.

The ultra-bright luminescent output of the Nluc-SiHa cell line transforms it into an exceptionally powerful tool for both in vitro analytics and complex preclinical animal modeling. In standard laboratory environments, the intense NanoLuc signal facilitates highly sensitive quantification of cell viability and proliferation. This makes it an ideal platform for high-throughput screening of novel chemotherapeutics, radiotherapies, and emerging targeted treatments, including those specifically aimed at neutralizing HPV oncoproteins. The superior signal-to-noise ratio is particularly advantageous for detecting early cellular responses during precise cytotoxicity assays. In preclinical animal studies, this reporter line serves as an optimal standard for establishing localized and metastatic models of human cervical cancer. Following subcutaneous or orthotopic implantation into immunodeficient mice, the brilliant NanoLuc signal enables high-sensitivity, non-invasive bioluminescence imaging (BLI). This capability empowers researchers to visually map early tumor engraftment, precisely track the localized progression of cervical malignancies, and dynamically evaluate the long-term therapeutic efficacy of experimental treatments in living subjects, drastically reducing the reliance on repeated animal sacrifices and destructive endpoint analyses.